Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -1.28% | 0.00% | +79.28% |
Chart calendar NGM Biopharmaceuticals, Inc.
Upcoming events on NGM Biopharmaceuticals, Inc.
Past events on NGM Biopharmaceuticals, Inc.
2024-04-08 16:30 | American Association for Cancer Research Meeting - Abstract No #3641 |
2024-04-08 16:30 | American Association for Cancer Research Meeting - Abstract No #CT099 |
2024-03-11 16:05 | Q4 2023 Earnings Release |
2024-03-05 09:10 | TD Cowen Health Care Conference |
2024-01-18 14:30 | B. Riley Securities Oncology Conference |
2023-11-29 08:45 | Evercore ISI HealthCONx Conference |
2023-11-13 | Jefferies London Healthcare Conference |
2023-11-09 | AASLD The Liver Meeting |
2023-11-02 16:01 | Q3 2023 Earnings Release |
2023-08-03 16:01 | Q2 2023 Earnings Release |
2023-06-12 17:00 | Goldman Sachs Global Healthcare Conference |
2023-06-08 09:00 | Jefferies Global Healthcare Conference |
2023-05-31 14:00 | Cowen Oncology Innovation Summit |
2023-05-09 | Annual General Meeting |
2023-05-04 16:05 | Q1 2023 Earnings Release |
2023-03-07 09:10 | Cowen Health Care Conference |
2023-02-28 16:05 | Q4 2022 Earnings Release |
2023-01-19 11:00 | B. Riley Securities Oncology Conference |
2022-12-09 | American Society of Hematology Meeting - Abstract #271 |
2022-12-09 | American Society of Hematology Meeting - Abstract #4082 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 104 91,2 13.6% | 87,4 89,1 -1.98% | 77,9 77,1 0.97% | 55,3 43,9 26% | 4,42 4,78 -7.57% |
EBITDA Million USD | Released Forecast Spread | -41,7 -39,0 -6.96% | -97,3 -97,0 -0.28% | -115 -115 0.18% | -162 -164 0.84% | -151 -164 8.15% |
EBIT Million USD | Released Forecast Spread | -49,3 -50,7 2.68% | -104 -111 6.49% | -120 -122 1.12% | -166 -171 2.81% | -151 -155 2.55% |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -42,8 -50,5 15.17% | -102 -110 6.62% | -120 -121 0.8% | -163 -169 3.93% | -142 -142 -0.58% |
Net income Million USD | Released Forecast Spread | -42,8 -50,5 15.17% | -102 -110 6.62% | -120 -121 0.8% | -163 -169 3.93% | -142 -142 -0.58% |
EPS USD | Released Forecast Spread | -0,85 -0,92 7.1% | -1,50 -1,66 9.48% | -1,56 -1,58 0.95% | -2,03 -2,11 3.88% | -1,73 -1,71 -0.97% |
Announcement Date | 17/03/20 | 04/03/21 | 01/03/22 | 28/02/23 | 11/03/24 |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 21,0 20,2 3.78% | 20,9 14,9 40.17% | 8,29 13,4 -38.11% | 7,91 7,06 11.99% | 18,2 6,77 168.72% | 2,25 6,14 -63.39% | 1,42 3,30 -56.93% | 0,58 2,60 -77.65% | 0,17 0,70 -76.35% |
EBITDA Million USD | Released Forecast Spread | -27,4 -29,6 7.24% | ||||||||
EBIT Million USD | Released Forecast Spread | -27,2 -28,2 3.48% | -32,6 -35,8 9.03% | -47,1 -41,9 -12.29% | -48,3 -47,7 -1.17% | -38,3 -43,1 11.16% | -50,2 -43,2 -16.16% | -40,6 -39,9 -1.79% | -31,0 -35,9 13.55% | -29,7 -33,6 11.79% |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -27,2 -28,2 3.44% | -32,5 -32,4 -0.16% | -46,5 -43,1 -7.82% | -47,3 -48,6 2.85% | -36,4 -43,1 15.44% | -47,6 -43,0 -10.88% | -38,3 -37,8 -1.27% | -28,8 -33,6 14.2% | -27,7 -26,8 -3.15% |
Net income Million USD | Released Forecast Spread | -27,2 -28,2 3.44% | -32,5 -32,4 -0.16% | -46,5 -43,1 -7.82% | -47,3 -48,6 2.85% | -36,4 -43,1 15.44% | -47,6 -43,0 -10.88% | -38,3 -37,8 -1.34% | -28,8 -33,6 14.2% | -27,7 -26,8 -3.15% |
EPS USD | Released Forecast Spread | -0,35 -0,37 4.11% | -0,42 -0,42 -0.6% | -0,59 -0,55 -7.27% | -0,59 -0,61 2.96% | -0,45 -0,52 13.46% | -0,58 -0,52 -10.69% | -0,46 -0,46 0% | -0,35 -0,40 13.04% | -0,33 -0,32 -2.06% |
Announcement Date | 01/03/22 | 05/05/22 | 04/08/22 | 03/11/22 | 28/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 11/03/24 |
Past sector events for NGM Biopharmaceuticals, Inc.
- Stock Market
- Equities
- NGM Stock
- Calendar NGM Biopharmaceuticals, Inc.